Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024.
華盛頓州溫哥華和紐約，2024年4月16日（GLOBE NEWSWIRE）——數據優先的生成人工智能藥物研發公司Absci公司（納斯達克股票代碼：ABSI）今天宣佈，該公司將在2024年5月14日星期二開市前報告第一季度的業務最新情況以及財務和經營業績。
Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating results, and outlook.
Absci管理層將從美國東部時間上午 8:00 /太平洋時間凌晨 5:00 開始網絡直播相應的電話會議，討論其業務發展、財務和經營業績以及前景。
Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
網絡直播的直播音頻將在該公司的投資者關係網站上提供，網址爲：investors.absci.com。網絡直播將在活動結束後存檔並可供重播。
About Absci
關於 Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci 是一家以數據爲先的生成式人工智能藥物研發公司，將人工智能與可擴展的溼實驗室技術相結合，以更快地爲患者創造更好的生物製劑。我們的 綜合藥物創造 平台通過同時優化對開發和治療益處都很重要的多種藥物特性，釋放了縮短臨床時間和提高成功概率的潛力。有了要訓練的數據，要創建人工智能，有待驗證的溼實驗室，我們每週可以篩查數十億個細胞，從而使我們能夠在短短六週內從人工智能設計的抗體轉變爲經溼式實驗室驗證的候選細胞。Absci的總部位於華盛頓州溫哥華，我們的人工智能研究實驗室位於紐約市，創新中心位於瑞士楚格。參觀 然後在 LinkedIn 上關注我們 (@absci)、X（推特）(@Abscibio)，以及 優酷。
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website () and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on X (Twitter), LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
有關 Absci 的其他信息的可用性
投資者和其他人應注意，我們會定期使用我們的網站與投資者和公衆溝通（) 和我們的投資者關係網站 (投資者.absci.com），包括但不限於通過在這些網站以及X（Twitter）、LinkedIn和YouTube上發佈投資者簡報、美國證券交易委員會文件、新聞稿、公開電話會議和網絡直播。我們在這些網站和社交媒體上發佈的信息可以被視爲重要信息。因此，鼓勵投資者、媒體和其他對Absci感興趣的人定期查看這些信息。根據經修訂的1933年《證券法》，我們的網站和社交媒體帖子或可能從我們的網站或社交媒體帖子訪問的任何其他網站的內容均不得被視爲以提及方式納入任何文件中。
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
投資者聯繫人
亞歷克斯·汗
財務與投資者關係副總裁
investors@absci.com
Media Contact
press@absci.com
媒體聯繫人
press@absci.com
譯文內容由第三人軟體翻譯。